ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,784.16
      -0.74%
      US Tech 100
      20,066.40
      -1.09%
      Dow Jones
      42,066.01
      0.30%
      Brent Oil
      80.235
      -0.47%
      Bitcoin
      92,422.02
      -2.19%
      Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Vanda Pharmaceuticals Inc (VNDA) Quote

      Vanda Pharmaceuticals Inc

      Vanda Pharmaceuticals Inc (VNDA)

      NASDAQ
      4.49
      -0.11
      ( -2.39% )
      Updated: 10:12:47
      Delayed by 15 minutes

      Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

      Premium

      Key stats and details

      Current Price
      4.49
      Bid
      4.49
      Ask
      4.50
      Volume
      96,870
      4.49 Day's Range 4.60
      3.46 52 Week Range 6.75
      Market Cap
      261.804M
      Previous Close
      4.60
      Open
      4.60
      Last Trade
      111
      @
      4.49
      Last Trade Time
      10:12:47
      Financial Volume
      $ 437,812
      VWAP
      4.5196
      Average Volume (3m)
      607,391
      Shares Outstanding
      58,308,144
      Dividend Yield
      -
      PE Ratio
      104.42
      Earnings Per Share (EPS)
      0.04
      Revenue
      192.64M
      Net Profit
      2.51M

      About Vanda Pharmaceuticals Inc

      Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improves the lives of patients. Its commercial portfolio comprises two products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder... Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improves the lives of patients. Its commercial portfolio comprises two products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and nighttime sleep disturbances in Smith-Magenis Syndrome (SMS) and Fanapt for the treatment of schizophrenia. Its other products include Tradipitant (VLY-686), VTR-297, and VQW-765. Show more

      Sector
      Pharmaceutical Preparations
      Industry
      Pharmaceutical Preparations
      Website
      www.vandapharma.com
      Headquarters
      Wilmington, Delaware, USA
      Founded
      -
      Vanda Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker VNDA. The last closing price for Vanda Pharmaceuticals was $4.60. Over the last year, Vanda Pharmaceuticals shares have traded in a share price range of $ 3.46 to $ 6.75.

      Vanda Pharmaceuticals currently has 58,308,144 shares outstanding. The market capitalization of Vanda Pharmaceuticals is $268.22 million. Vanda Pharmaceuticals has a price to earnings ratio (PE ratio) of 104.42.

      Ask ADVFN Intelligence (AI)

      VNDA Latest News

      More News

      Vanda's Letter to FDA Commissioner Highlights Faulty Gastroparesis NDA Review

      Vanda's Letter to FDA Commissioner Highlights Faulty Gastroparesis NDA Review PR Newswire WASHINGTON, Jan. 8, 2025 WASHINGTON, Jan. 8, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda...

      January 08 2025
      PR Newswire (US)

      Vanda Pharmaceuticals Announces Orphan Drug Designation Granted for VGT-1849A, a Novel and Selective Antisense Oligonucleotide Candidate for the Treatment of Polycythemia Vera

      Vanda Pharmaceuticals Announces Orphan Drug Designation Granted for VGT-1849A, a Novel and Selective Antisense Oligonucleotide Candidate for the Treatment of Polycythemia Vera PR...

      December 20 2024
      PR Newswire (US)

      Form 4 - Statement of changes in beneficial ownership of securities

      November 18 2024
      Edgar (US Regulatory)

      Form 144 - Report of proposed sale of securities

      November 14 2024
      Edgar (US Regulatory)

      Vanda Pharmaceuticals Announces Participation at November 2024 Investor Conferences

      Vanda Pharmaceuticals Announces Participation at November 2024 Investor Conferences PR Newswire WASHINGTON, Nov. 12, 2024 WASHINGTON, Nov. 12, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc...

      November 12 2024
      PR Newswire (US)

      Form 10-Q - Quarterly report [Sections 13 or 15(d)]

      November 07 2024
      Edgar (US Regulatory)

      Form 8-K - Current report

      November 06 2024
      Edgar (US Regulatory)

      Vanda Pharmaceuticals Reports Third Quarter 2024 Financial Results

      Vanda Pharmaceuticals Reports Third Quarter 2024 Financial Results PR Newswire WASHINGTON, Nov. 6, 2024 Revenues for Q3 2024 were $47.7 million, an increase of 23% compared to Q3 2023Financial...

      November 06 2024
      PR Newswire (US)

      Vanda Pharmaceuticals to Announce Third Quarter 2024 Financial Results on November 6, 2024

      Vanda Pharmaceuticals to Announce Third Quarter 2024 Financial Results on November 6, 2024 PR Newswire WASHINGTON, Oct. 30, 2024 Conference Call and Webcast to Follow WASHINGTON, Oct. 30, 2024...

      October 30 2024
      PR Newswire (US)

      Form 8-K - Current report

      October 15 2024
      Edgar (US Regulatory)
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      1-0.35-7.231404958684.844.954.435620824.72271463CS
      4-0.11-2.391304347834.64.9554.435325134.72942602CS
      12-0.44-8.924949290064.935.5454.436073914.8656447CS
      26-1.3-22.45250431785.796.3654.356174355.05810468CS
      520.6316.32124352333.866.753.4611905904.97954257CS
      156-10.11-69.246575342514.615.263.2958461206.20540458CS
      260-11.46-71.849529780615.9521.86273.2957209758.54779379CS

      VNDA - Frequently Asked Questions (FAQ)

      What is the current Vanda Pharmaceuticals share price?
      The current share price of Vanda Pharmaceuticals is $ 4.49
      How many Vanda Pharmaceuticals shares are in issue?
      Vanda Pharmaceuticals has 58,308,144 shares in issue
      What is the market cap of Vanda Pharmaceuticals?
      The market capitalisation of Vanda Pharmaceuticals is USD 268.22M
      What is the 1 year trading range for Vanda Pharmaceuticals share price?
      Vanda Pharmaceuticals has traded in the range of $ 3.46 to $ 6.75 during the past year
      What is the PE ratio of Vanda Pharmaceuticals?
      The price to earnings ratio of Vanda Pharmaceuticals is 104.42
      What is the cash to sales ratio of Vanda Pharmaceuticals?
      The cash to sales ratio of Vanda Pharmaceuticals is 1.36
      What is the reporting currency for Vanda Pharmaceuticals?
      Vanda Pharmaceuticals reports financial results in USD
      What is the latest annual turnover for Vanda Pharmaceuticals?
      The latest annual turnover of Vanda Pharmaceuticals is USD 192.64M
      What is the latest annual profit for Vanda Pharmaceuticals?
      The latest annual profit of Vanda Pharmaceuticals is USD 2.51M
      What is the registered address of Vanda Pharmaceuticals?
      The registered address for Vanda Pharmaceuticals is CORPORATION TRUST CENTER, 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
      What is the Vanda Pharmaceuticals website address?
      The website address for Vanda Pharmaceuticals is www.vandapharma.com
      Which industry sector does Vanda Pharmaceuticals operate in?
      Vanda Pharmaceuticals operates in the PHARMACEUTICAL PREPARATIONS sector

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      PHIOPhio Pharmaceuticals Corporation
      $ 5.82
      (244.38%)
      		107.24M
      SLRXSalarius Pharmaceuticals Inc
      $ 3.99
      (154.95%)
      		51.7M
      ATPCAgape ATP Corporation
      $ 2.30
      (82.54%)
      		50.1M
      LITMSnow Lake Resources Ltd
      $ 0.911
      (34.19%)
      		22.08M
      ITCIIntra Cellular Therapies Inc
      $ 127.2701
      (34.15%)
      		13.36M
      SVMHSRIVARU Holding Ltd
      $ 0.0397
      (-35.76%)
      		80.84M
      CMTLComtech Telecommunications Corporation
      $ 2.8097
      (-31.97%)
      		899.63k
      SMXSMX Security Matters Public Company
      $ 0.273281
      (-31.88%)
      		8.72M
      NAYANAYA Biosciences Inc
      $ 0.58
      (-28.69%)
      		526.8k
      AIRSAirSculpt Technologies Inc
      $ 4.29
      (-28.26%)
      		274.27k
      GCTKGlucoTrack Inc
      $ 0.1437
      (22.82%)
      		469.67M
      PHIOPhio Pharmaceuticals Corporation
      $ 5.8701
      (247.34%)
      		107.35M
      BHATBlue Hat Interactive Entertainment Technology
      $ 0.064
      (-27.36%)
      		89.24M
      SVMHSRIVARU Holding Ltd
      $ 0.0397
      (-35.76%)
      		80.84M
      RIMEAlgorhythm Holdings Inc
      $ 0.099549
      (-26.15%)
      		65.8M

      VNDA Discussion

      View Posts
      eyeownu eyeownu 2 months ago
      im a buyer at 5.07.nice triangle has formed. low float. plenty of cash on balance sheet. book value 9.20/sh
      👍️0
      Zilla Zilla 3 months ago
      WOW talk about being lucky. Bought calls Friday for 2025 just in case something happens in 2024. Up 20% pre-market with an 8 all cash offer on the table.
      👍️0
      Monksdream Monksdream 4 months ago
      VNDA under $7
      👍️0
      harry crumb harry crumb 6 months ago
      Watching this closely
      👍️0
      Monksdream Monksdream 6 months ago
      VNDA under $10
      👍️0
      Monksdream Monksdream 7 months ago
      Early Barchart 100
      https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
      👍️0
      Monksdream Monksdream 7 months ago
      Over $6
      👍️0
      tw0122 tw0122 7 months ago
      Vanda acquired U.S. and Canadian rights to PONVORY® from a Johnson & Johnson Company on December 7, 2023. PONVORY® is approved by the U.S. Food and Drug Administration (FDA) and Health Canada to treat adults with relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease (RMS).

      In anticipation of the commercial launch of PONVORY® for RMS in the third quarter of 2024, Vanda is initiating a host of commercial activities including the creation of a specialty sales force, a prescriber awareness program and a comprehensive marketing program.
      👍️0
      harry crumb harry crumb 8 months ago
      Gonna be a winner. Patience
      👍️0
      harry crumb harry crumb 8 months ago
      Over 5$!
      👍️0
      Monksdream Monksdream 8 months ago
      VNDA under $5
      👍️0
      harry crumb harry crumb 8 months ago
      Let er rip $$$$$$$$
      👍️0
      Tiger Money Tiger Money 9 months ago
      Agreed. This could double quickly
      👍️0
      philaya philaya 9 months ago
      got this today...
      very good trades.
      👍️0
      harry crumb harry crumb 9 months ago
      This little gem could run up fast, they obviously have their science going in the right direction as the offers are there just not the price, could be a 10.00 offer in the works
      👍️0
      morokoy morokoy 9 months ago
      Shares Outstanding 57,537,499 shares
      Insider Shares 7,908,897 shares
      Insider Ownership 13.75 %
      Total Insiders 34
      👍️0
      morokoy morokoy 9 months ago
      "The dividend distribution of rights will be payable to stockholders of record as of the close of business on April 29, 2024."

      A shareholder may also receive distributions such as additional stock or stock rights in the distributing corporation; such distributions may or may not qualify as dividends.

      A shareholder may also receive distributions such as additional stock or stock rights in the distributing corporation; such distributions may or may not qualify as dividends. You should receive a Form 1099-DIV, Dividends and Distributions from each payer for distributions of at least $10.

      Guess we'll have to wait on the promised 8K.

      Additional details of the Rights Plan will be contained in a Form 8-K to be filed by the Company with the U.S. Securities and Exchange Commission (the "SEC"). The filing will be available on the SEC's website at www.sec.gov.
      👍️0
      harry crumb harry crumb 9 months ago
      Minimum 8$ imo
      👍️0
      MiamiGent MiamiGent 9 months ago
      Vanda Pharmaceuticals rejects takeover proposal from Future Pak
      REUTERS
      1 mins ago
      April 17 (Reuters) - Vanda Pharmaceuticals Inc (VNDA.NaE) on Wednesday said it is rejecting a takeover proposal from Future Pak, a privately-held contract manufacturer and packager of pharmaceuticals, as it significantly undervalues the company.

      (Reporting by Sriparna Roy in Bengaluru; Editing by Tasim Zahid)
      👍️0
      Monksdream Monksdream 9 months ago
      Early Barchart 100
      https://www.barchart.com/stocks/performance/percent-change/advances?orderBy=percentChange&orderDir=desc
      👍️ 1
      MiamiGent MiamiGent 9 months ago
      Probably...but I took it at 5.49
      👍️0
      Monksdream Monksdream 9 months ago
      Will it grow legs after 9:30
      👍️0
      MiamiGent MiamiGent 9 months ago
      VNDA Vol picking up..

      $5.49 +$1.44 (+35.56%)

      Volume 3,354,569

      90 DAV... 2M
      👍️0
      MiamiGent MiamiGent 9 months ago
      VNDA Here we go
      $5.3781 +$1.3281 (32.79%)

      Bid ARCX
      5.36 x 10
      Ask XNMS
      5.38 x 11
      Volume
      2,971,106
      👍️0
      MiamiGent MiamiGent 9 months ago
      VNDA Vol is good. Already @ 90 DAV
      Volume 2,056,421
      10/90-day avg. volume
      7M / 2M
      👍️0
      MiamiGent MiamiGent 9 months ago
      VNDA Good post, Laster.
      https://www.futurepak.com/
      👍️0
      Laster Laster 9 months ago
      The major question is who is Future Pak really?
      Is this a legit offer?
      Either way, company is extremely undervalued with no debt (I believe) and lots of cash.
      Large short position. Lots of selling PM at $5.
      Market does not seem to believe this offer. Sorry.
      👍️0
      MiamiGent MiamiGent 9 months ago
      VNDA Float 52.05M

      Shares Short (3/28/2024) 2.49M
      Short Ratio (3/28/2024) 2.78
      Short % of Float (3/28/2024) 5.45%
      👍️0
      MiamiGent MiamiGent 9 months ago
      VNDA
      Bid EDGX
      4.85 x 3
      Ask EDGX
      4.88 x 3

      Volume
      1,790,654
      Avg Vol (10 day) 6.63M
      👍️0
      MiamiGent MiamiGent 9 months ago
      Vanda Pharmaceuticals
      Closed .01 (-0.25%)

      Pre-market
      $5.15 +1.10 (+27.16%)
      As of Apr-17-2024 7:23:52 AM ET
      Bid x size $5.14 x 1
      Ask x size $5.16 x 3
      👍️0
      MiamiGent MiamiGent 9 months ago
      VNDA In 5.12. Let's see, said the blind man.
      👍️0
      MiamiGent MiamiGent 9 months ago
      Vanda Pharmaceuticals jumps 38% on Future Pak's latest buy offer
      Apr. 17, 2024 6:41 AM ETVanda Pharmaceuticals Inc. (VNDA) Stock
      👍️0
      MiamiGent MiamiGent 9 months ago
      What's the news?
      👍️0
      Awl416 Awl416 9 months ago
      Damn
      👍️0
      Monksdream Monksdream 9 months ago
      Will it grow legs after 9:30
      👍️0
      Monksdream Monksdream 9 months ago
      Will it grow legs after 9:30
      👍️0
      tknuncle tknuncle 11 months ago
      I have been acquiring since $3.90. I wish that I would have waited longer lol but, like what I see with VNDA. Was going to grab the last of my starter position soon. GLTA
      👍️0
      weedtrader420 weedtrader420 11 months ago
      FDA Approve
      👍️0
      Triple nickle Triple nickle 1 year ago
      Fda accepts new drug application for tradipitant in the after hours today
      👍️ 1
      jgrabar jgrabar 3 years ago
      $VNDA -On May 19, 2022, Vanda Pharmaceuticals agreed to settle a securities fraud class action complaint (the “Complaint”) for $11.5 Million. https://grabarlaw.com/the-latest/vanda-pharmaceuticals-investigation/
      👍️0
      RNsidersbuying RNsidersbuying 4 years ago
      VNDA 12.34 - FDA Approves HETLIOZ® (tasimelteon) for the Treatment of Nighttime Sleep Disturbances in Smith-Magenis Syndrome

      https://ih.advfn.com/stock-market/NASDAQ/vanda-pharmaceuticals-VNDA/stock-news/83807075/fda-approves-hetlioz-tasimelteon-for-the-treatmen
      👍️0
      XenaLives XenaLives 4 years ago
      Everything would be a lot better if the govt. would just let doctors treat COVID like another flu bug. The drama is getting old.
      👍️0
      Peepson Peepson 4 years ago
      Yo, this thing is going to trade sideways for a while. They have a drug that could help with covid but so does every other pharma company. Its a safe hold imo but nothing will happen fast i don't think
      👍️0
      XenaLives XenaLives 4 years ago
      What's up? Doesn't seem to be much interest. I was looking at the chart but haven't found much on the company yet.

      👍️0
      otcmoneydoubler otcmoneydoubler 5 years ago
      LOL. VNDA GOT NEWS TODAY. SO WHAT DD HAVE YOU GOT TO SHARE?
      👍️0
      Peepson Peepson 5 years ago
      Yo, does anyone still follow this board. I might have some interesting dd to share.
      👍️0
      bezen bezen 8 years ago
      https://finance.yahoo.com/news/jefferies-5-top-biotech-stocks-133534894.html
      👍️0
      Coz Mabluda Coz Mabluda 8 years ago
      Brett Jensen. SA article re VNDA. Expects positive analyst's review.

      Vanda Pharmaceuticals (NASDAQ:VNDA) posted solid third quarter results on Thursday. Instead of losing a dime a share as expected, the company posted a profit of 11 cents a share. Revenue was also up more than 35% from the same period a year ago. The company now looks like it could be profitable in FY2017. I expect some positive analyst commentary on this name by analysts over the next week. Vanda has a solid pipeline and over $140 million in cash and marketable securities on the balance sheet. One has to like the company's growth trajectory and the concern seems undervalued with just a $600 million market capitalization.



      👍️0
      stocktrademan stocktrademan 8 years ago
      fast and steady profit scan VNDA bullish 16.64



      normal chart


      log chart

      👍️0
      ClearlyStocks ClearlyStocks 8 years ago
      VNDA $16.74
      👍️0

      Your Recent History

      NASDAQ
      VNDA
      Vanda Pharmaceuticals
      Delayed Upgrade Clock

      Go Ad-Free

      Subscribe to Ad free and enjoy an ad-free experience

      No Ads

      Try Now

      Keep the Ads